Tab. 2.
Growth inhibitory concentration (GI50, μM) of compounds 4e, 4f, and 4i by cell linesa.
| Disease | 4e | 4f | 4id | Disease | 4e | 4f | 4id |
|---|---|---|---|---|---|---|---|
| Leukemia | CNS cancer | ||||||
| CCRF-CEM | 23.40 | 4.38 | 3.19 (1.84) | SF-268 | 14.10 | 4.89 | 2.53 (3.30) |
| HL-60(TB) | 15.20 | 1.98 | 2.01 (1.26) | SF-295 | 5.78 | 3.77 | 1.71 (1.14) |
| K-562 | 19.40 | 4.97 | NAc (1.98) | SF-539 | 16.70 | 3.17 | 3.26 (3.46) |
| MOLT-4 | 17.30 | 3.88 | 2.77 (3.67) | SNB-19 | 11.30 | 4.49 | 2.41 (2.85) |
| RPMI-8226 | 14.50 | 4.64 | 1.93 (1.33) | SNB-75 | 7.76 | 6.64 | 1.26 (0.67) |
| SR | 13.80 | 3.96 | 41.40 (1.96) | U251 | 15.10 | 4.27 | 1.63 (2.21) |
|
| |||||||
| NSCL cancer | Prostate cancer | ||||||
| A549/ATCC | 3.16 | 2.35 | 1.34 (0.65) | PC-3 | 17.70 | 5.41 | 1.98 (2.57) |
| EKVX | 16.30 | 4.97 | 3.24 (4.03) | DU-145 | 4.19 | 1.68 | 0.51 (0.93) |
|
|
|||||||
| HOP-62 | 14.90 | 5.87 | 0.40 (3.60) | Ovarian cancer | |||
| HOP-92 | 11.50 | 5.26 | 1.44 (2.15) | IGROV-1 | 15.40 | 3.35 | 2.48 (NT) |
| NCI-H226 | 19.20 | 5.43 | 1.74 (2.85) | OVCAR-3 | 11.20 | 3.01 | 1.03 (0.57) |
| NCI-H23 | 3.99 | 1.68 | 0.95 (0.41) | OVCAR-4 | 4.48 | 2.48 | 2.19 (1.33) |
| NCI-H322M | 10.90 | 3.78 | 2.05 (1.86) | OVCAR-5 | 32.10 | 17.70 | 10.40 (4.49) |
| NCI-H460 | 5.39 | 2.18 | 1.92 (1.66) | OVCAR-8 | 13.90 | 4.02 | 2.85 (2.05) |
| NCI-H522 | 15.90 | 7.91 | 1.96 (2.12) | SK-OV-3 | 31.70 | 13.60 | 8.28 (5.72) |
|
| |||||||
| Melanoma | Renal cancer | ||||||
| LOX IMVI | 8.03 | 1.26 | 0.16 (0.25) | 786-0 | 32.60 | 15.20 | 2.60 (5.20) |
| MALME-3M | 7.12 | 2.12 | 0.72 (1.05) | A498 | 20.50 | 4.91 | 1.95 (2.11) |
| M14 | 6.90 | 2.67 | 1.25 (1.22) | ACHN | 17.80 | 9.24 | 2.95 (1.66) |
| SK-MEL-2 | 20.30 | 4.19 | 2.21 (0.98) | CAKI-1 | 17.40 | 11.20 | 1.50 (2.92) |
| SK-MEL-28 | 12.20 | 6.22 | 1.79 (1.41) | RXF-393 | 6.98 | 2.27 | 2.52 (NT) |
| SK-MEL-5 | 2.62 | 1.52 | 0.96 (0.48) | SN12C | 15.30 | 3.68 | NT (3.02) |
| UACC-257 | 11.30 | 6.13 | 1.31 (0.22) | TK-10 | 29.70 | 17.60 | 5.74 (2.16) |
| UACC-62 | 12.50 | 2.21 | 0.43 (1.59) | UO-31 | 5.62 | 10.80 | 3.33 (0.57) |
|
| |||||||
| Breast cancer | Colon cancer | ||||||
| MCF-7 | 12.90 | 2.25 | 1.07 (2.26) | COLO 205 | 10.30 | 3.37 | 2.08 (1.68) |
| NCI/ADR-RES | 22.70 | 7.07 | 8.39 (4.50) | HCC-2998 | 16.60 | NTb | 3.77 (3.24) |
| HS 578T | 4.52 | 3.71 | 0.27 (0.65) | HCT-116 | 15.60 | 3.47 | 3.36 (2.46) |
| MDA-MB-435 | 12.00 | 2.19 | 1.38 (1.48) | HCT-15 | 11.50 | 3.51 | 2.07 (1.74) |
| BT-549 | 13.40 | 2.84 | 2.74 (0.92) | HT29 | 11.20 | 3.15 | 2.35 (2.02) |
| T-47D | 16.10 | 3.42 | 2.56 (2.56) | KM12 | 16.90 | 5.99 | 2.25 (2.51) |
| MDA-MB-468 | NT | NT | NT (1.75) | SW-620 | 22.70 | 3.96 | 2.82 (3.23) |
| MDA-MB-231/ATCC | 7.81 | 3.13 | 0.86 (1.98) | ||||
a
Data obtained from NCI’s in vitro disease-oriented human tumor cell screen;
b
NT, Not Tested;
c
NA, not active; GI50 >100 μM;
d
In parentheses the data of repeated testing.